Pledin Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Taeguk Pharmaceutical Co., Ltd.
MFDS item code 201902234 · Approved 2019.04.11
This product's status changed to Expired on 2024.04.11. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also helpful as an adjunctive treatment when partial seizures occur in patients with epilepsy. Additionally, it is effective in alleviating the symptoms of fibromyalgia. This drug contributes to improving the quality of life for patients by addressing various nerve-related pains and symptoms. Therefore, it is used for the treatment of neuralgia, epilepsy, and fibromyalgia.
This medication should be administered orally, with or without food, as the total daily dose of pregabalin divided into 2 doses. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is excreted primarily by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. For women, multiply the result obtained from the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behavior; if mood changes or symptoms of depression occur during treatment, consult a doctor immediately. Do not take this medication if you are allergic to any of its components or if you have genetic issues such as lactose intolerance. Diabetic patients may require adjustments in the dosage of blood sugar control medications due to weight gain after using this medication. This medication can cause severe allergic reactions such as angioedema, so if you experience swelling of the face or neck and difficulty breathing, stop taking it immediately and go to the hospital. Elderly patients should be cautious as dizziness or drowsiness may occur, increasing the risk of falls or injuries. Some patients may experience blurred vision or changes in vision after taking this medication, and if symptoms are severe, consult with a physician. Abruptly stopping this medication may lead to withdrawal symptoms such as insomnia, headache, anxiety, and nausea, so it should be gradually reduced under a doctor's supervision. Due to the potential for drug abuse, patients with a history of substance abuse or mental health issues should consult with healthcare professionals before taking this medication. Patients with impaired kidney function may need dosage adjustments, and those with heart conditions should also use this medication with caution. Taking this medication with other central nervous system depressants or alcohol can intensify side effects such as drowsiness or respiratory depression, so caution is required. In early pregnancy, it could affect the fetus, so pregnant women should avoid taking this medication, and women of childbearing age should use effective contraceptive methods. While breastfeeding, this medication may pass into breast milk and affect the baby, so breastfeeding should be stopped or its use should be discussed with a physician. During treatment, dizziness or drowsiness may occur, so it is safest to avoid driving or operating hazardous machinery. In case of overdose, symptoms such as confusion, drowsiness, and depression may appear, so it is crucial to adhere to the prescribed dosage and inform healthcare providers of any unusual symptoms immediately. Keep out of reach of children and do not transfer to other containers.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent air or moisture from entering, and keep it in a cool place between 15 and 30 degrees Celsius. This will help maintain the effectiveness of the drug.
A hard capsule with white powder inside, with a white body and cap.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 150mg
Hard capsule · Prescription medication
Taeguk Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.